Precision BioSciences
Agent45Agent Readiness: 45/100. Above median. Measured by StartupHub.ai. Median 41.Trust85Data Trust: 85/100. Top 25%. Measured by StartupHub.ai. Median 61.A clinical-stage biotechnology company developing in vivo gene editing therapies.
About
Precision BioSciences is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies for genetic diseases. They leverage their proprietary ARCUS genome engineering platform to create novel therapies that aim to correct disease-causing mutations within a patient's own cells. Their lead product candidate, PBCAR0191, is being developed for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r ALL) and non-Hodgkin lymphoma (NHL).
Listed competitors
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
Global provider of integrated temperature-controlled supply chain solutions for the life sciences industry.
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Clinical-stage biopharmaceutical company developing novel treatments for serious ischemic and vascular diseases.
Also in this space
A biotechnology company developing genetic therapies for rare disorders.
Shares Biotechnology, Pharmaceuticals
Scalable, one-time curative in-vivo gene editing therapies.
Shares Biotechnology, Genetics
Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).
Shares Biotechnology, Pharmaceuticals
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Biotechnology company focused on developing cancer immunotherapies.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- precisionbiosciences.com
- Headquarters
- Durham, North Carolina, USA
- Founded
- 2006
- Employees
- 97
- Total funding
- $358M (Milestone Payment)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 2 Mar 2026 | Milestone Payment | $8M | |
| 10 Nov 2025 | Offering | $75M | |
| 4 Sept 2024 | Funding Round | $13M | |
| 28 Mar 2019 | IPO | $126M | |
| 8 Jun 2018 | Series B | $110M | |
| 25 May 2015 | Series A | $26M |
Tech stack
Detected on precisionbiosciences.com, last scanned 23 Oct 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Hosting
- Google Cloud
- Email provider
- Microsoft 365
Precision BioSciences scores 56. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
What does Precision BioSciences do?
The company also has a strategic collaboration with TG Therapeutics for the development of a CAR T therapy for multiple sclerosis.
Is Precision BioSciences trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Precision BioSciences is 85 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Precision BioSciences raised?
Precision BioSciences has raised a total of $358M in funding. The most recent round on record is Milestone Payment.
How many employees does Precision BioSciences have?
Precision BioSciences has approximately 97 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Precision BioSciences
